FARE Blog

Thank you to everyone who took part in the Contains: Courage® FARE Summit 2019!

We’re grateful to everyone who took part in Teal Pumpkin Project® 2019. Your commitment to the health and happiness of children with food allergies made a difference both nationally and globally this year.

This week, FARE is thrilled to celebrate its three-year partnership with OWYN – Only What You Need. OWYN is a 100 percent plant-based protein product free from the top eight allergens. Even more exciting, OWYN is a proud champion of the food allergy community and supports FARE’s mission to improve the quality of life and the health of individuals with food allergies.

Hi, my name is Rachel Blum and I am a 16-year-old living in Deerfield, Illinois. I have a severe food allergy to peanuts and tree nuts, and I was diagnosed when I was about 7 years old. This blog post is about enjoying Halloween with food allergies.

What’s up, y’all? I’m Anesha Santhanam, and I’m back with tips for rising juniors and incoming seniors who are navigating the college search with food allergies.

It’s no secret that plant-based diets are increasing in popularity. The Plant Based Foods Association reported in a 2018 Nielsen study that plant-based food sales topped $3.3 billion last year. Specifically, sales of plant-based meat products have grown by 24%, which is notable since general retail food sales have only grown by 2% over the same time.

With the right preparation for the trip and enough allergy-safe snacks brought from home, it is possible to experience the world while being safe.

Whether you’re preparing for a future college search, deeply engaged in the applications process, or already attending university, it’s important to understand the rights of post-secondary students with a history of severe food allergy reactions.

The food allergy community needs better labeling, access to real treatments and, ultimately, a cure. FARE tackled each of these challenges this summer.

Today, Food and Drug Administration (FDA) panelists voted to recommend the approval of Aimmune Therapeutics’ groundbreaking peanut allergy treatment, AR101, for patients aged 4-17.